Şekerdağ, EmineLüle, SevdaBozdağ Pehlivan, SibelÖztürk, NaileKara, AslıKaffashi, AbbasVural, İmranIşıkay, İlkayYavuz, BurçinKarlı Oğuz, Hatice KaderSöylemezoğlu, FigenGürsoy Özdemir, YaseminMut, Melike2019-05-102019-05-102017Sekerdag, E., Lüle, S., Pehlivan, S. B., Öztürk, N., Kara, A., Kaffashi, A., ... & Söylemezoğlu, F. (2017). A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles. Journal of Controlled Release, 261, 187-198.0168-3659https://doi.org/10.1016/j.jconrel.2017.06.032https://hdl.handle.net/11491/742New drug delivery systems are highly needed in research and clinical area to effectively treat gliomas by reaching a high antineoplastic drug concentration at the target site without damaging healthy tissues. Intranasal (IN) administration, an alternative route for non-invasive drug delivery to the brain, bypasses the blood-brainbarrier (BBB) and eliminates systemic side effects. This study evaluated the antitumor efficacy of farnesylthiosalicylic acid (FTA) loaded (lipid-cationic) lipid-PEG-PLGA hybrid nanoparticles (HNPs) after IN application in rats. FTA loaded HNPs were prepared, characterized and evaluated for cytotoxicity. Rat glioma 2 (RG2) cells were implanted unilaterally into the right striatum of female Wistar rats. 10 days later, glioma bearing rats received either no treatment, or 5 repeated doses of 500 mu M freshly prepared FTA loaded HNPs via IN or intravenous (IV) application. Pre-treatment and post-treatment tumor sizes were determined with MRI. After a treatment period of 5 days, IN applied FTA loaded HNPs achieved a significant decrease of 55.7% in tumor area, equal to IV applied FTA loaded HNPs. Herewith, we showed the potential utility of IN application of FTA loaded HNPs as a non-invasive approach in glioblastoma treatment.eninfo:eu-repo/semantics/closedAccessDrug DeliveryFarnesylthiosalicylic AcidGlioblastomaHybrid NanoparticlesNose-to-BrainArticle26118719810.1016/j.jconrel.2017.06.032N/AQ1